Auna's Third Quarter Must Prove Margin Recovery Can Catch Up With Solid Revenue

Auna heads into its third-quarter report with a familiar problem: patients keep coming, cash keeps piling up, yet profits have not followed. Management spent the last call promising a stronger second half, but it also trimmed its earnings outlook and carved out a recurring Peru billing problem from guidance. The results due after the close on November 17 are the first real chance to see whether that promised rebound shows up in margins, or whether the Latin American hospital operator is simply growing revenue it cannot convert.

The Street is asking for a lot on the bottom line. Consensus calls for earnings of $0.27 per share, up 35% from $0.20 a year ago and well above the $0.15 reported last quarter. Revenue is expected at about $362.6 million, a solid 12.6% increase from the year-ago period but essentially flat with the $363.0 million booked in the second quarter. Put simply, analysts are modeling a sharp profit improvement on a stable revenue base, which makes this a margin quarter above all else. Management reaffirmed full-year revenue of roughly $1.378 billion, while consensus sits near $1.41 billion, so the Street is already leaning above the company's own top-line outlook. That leaves little room for a revenue stumble to be forgiven.

The last call explains why margins are the swing factor. Revenue grew 9% on a currency-neutral basis, helped by a richer mix of high-complexity care, but adjusted EBITDA fell 9%, and every market weakened. Mexico swung from strong growth to a 16% decline, Colombia went from modest gains to a 12% drop, and Peru was flat only because billing penalties tied to prior-year payer reconciliations returned and grew after being framed as largely one-off. Management now sees full-year EBITDA growth toward the low end of its 10% to 14% range, and only excluding those Peru penalties. Validation this quarter would mean Peru penalties shrinking or being resolved, Mexico absorbing the new insurance VAT and B2B onboarding costs, and Colombia's margin improvement from the second quarter continuing despite minimum-wage pressure. Another round of penalties, or EBITDA declining again, would suggest the low-end guide is still too generous.

There are genuine operating positives to look for. Mexico's oncology revenue more than doubled year over year, surgical and chemotherapy volumes accelerated sequentially, and the ELEKTA linear accelerator in Monterrey was slated to open in September, adding higher-margin radiotherapy just as this quarter closed. In Colombia, risk-sharing contracts climbed to 24% of revenue while exposure to intervened payers fell to 12%, a shift that should improve collection quality over time. Free cash flow was the standout, up 181% year to date, and leverage edged down to 3.6x on the way toward a sub-3x target. Continued cash strength and further deleveraging would support the thesis even if margins only stabilize.

The market is cautiously giving Auna the benefit of the doubt. Shares are up 1.5% since the last report while the S&P 500 fell 2.3%, and sentiment, though still bearish, has softened slightly from the prior quarter. Still, at $4.71 the stock sits below its 200-day moving average near $5.11 and in the lower part of its post-earnings range of $4.41 to $5.64, hardly a sign of conviction.

The verdict hinges on profit conversion. If Auna delivers sequential EBITDA improvement in all three markets and shows the Peru penalties fading, the second-half recovery story regains credibility. If revenue holds but margins slip again, the narrative shifts from temporary headwinds to a structurally tougher payer environment.

This earnings preview was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It is AI-assisted, based on proprietary Earnings Whispers data and company reports, and edited by Earnings Whispers staff.